A Novel Nitric-Oxide Releasing Drug
- Technology Benefits
- Direct release of NO at physiological temperature and pH. More potent than equimolar amounts of nitroglycerin. Development of patient tolerance should not occur. No toxic by-products or concurrently released agents. Repeated administration regimens or development of time released formulations possible.
- Detailed Technology Description
- This hypertensive agent, nitrosyl-cobinamide, is a direct NO releasing agent that does not require biotransformation, thereby avoiding the concurrent release of toxic metabolites (superoxide ions, peroxynitrate, or cyanide ions). Cobinamide is a precursor of Vitamin B12 and appears to be metabolically neutral at the doses used for this indication. It has been tested in mammalian cells, Drosophila melanogaster and mice, where a rapid reduction of blood pressure was demonstrated.
- Supplementary Information
- Patent Number: US9093654B2
Application Number: US13022242A
Inventor: Che, Chi Ming | Xiang, Hai Feng
Priority Date: 9 Feb 2010
Priority Number: US9093654B2
Application Date: 7 Feb 2011
Publication Date: 28 Jul 2015
IPC Current: H01L005146 | B82Y001000 | H01L00310224 | H01L005100 | H01L005130 | H01L005142
US Class: 1001
Assignee Applicant: The University of Hong Kong
Title: Bis-(8-quinolinolato-N,O)platinum(II) based organic photovoltaic cell
Usefulness: Bis-(8-quinolinolato-N,O)platinum(II) based organic photovoltaic cell
Summary: The organic photovoltaic cell is useful to generate electricity.
Novelty: Organic photovoltaic cell, useful to generate electricity, comprises an organic photoactive layer comprising substituted bis-(8-quinolinolato-N,O)platinum(II) complexes
- Industry
- Functional Design
- Sub Category
- Mechanical Structure
- Application No.
- 8222242
- Others
-
State Of Development
Development for the use of this compound is at the prototype stage and efficacy in reducing blood pressure has been demonstrated. Ongoing pre-clinical studies continue, including pharmacokinetic and toxicology.
Additional Technologies by these Inventors
Tech ID/UC Case
19637/2007-196-0
Related Cases
2007-196-0
- *Abstract
-
Typically used to treat a variety of cardiac conditions, most nitric oxide generating drugs are organic nitrates (such as nitroglycerin) that require metabolic conversion in order to release NO. Many of these organic compounds have limited suitability for long-term use. Tolerance can develop in the patient and the number of NO molecules available may be restricted due to toxicity caused by either metabolic by-products or concurrently released moieties such as cyanide. Therefore, a need for a potent, non-toxic agent that releases NO directly exists and could provide a desirable alternative to patients suffering from hypertension, congestive heart failure or other conditions where fast, effective vasodilation is required.
- *IP Issue Date
- Jul 17, 2012
- *Principal Investigator
-
Name: Gerry Boss
Department:
Name: Kate Broderick
Department:
Name: Vijay Sharma
Department:
- Country/Region
- USA
For more information, please click Here
